| Literature DB >> 26996776 |
Shu-Yu Tai1,2,3,4, Hui-Min Hsieh5, Shu-Pin Huang6,7, Ming-Tsang Wu8,9,10.
Abstract
BACKGROUND: This study investigated the effects that hair dye use and regular exercise exert on the risk and prognosis of prostate cancer.Entities:
Keywords: Case–control study; Hair dye; Prostate cancer; Regular exercise; Risk; Survival
Mesh:
Substances:
Year: 2016 PMID: 26996776 PMCID: PMC4800765 DOI: 10.1186/s12885-016-2280-7
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Fig. 1Study flowchart
Demographic and clinical characteristics of the 296 matched case–control study and the 608 case-only study
| Cases | Controls | All cases | ||||||
|---|---|---|---|---|---|---|---|---|
| Variables |
|
|
|
| ||||
| N | (%) | N | (%) | N | (%) | Deatha ( | ||
| Study site1 | ||||||||
| South | 296 | (100.0) | 296 | (100.0) | 227 | (37.3) | 19 | |
| North | - | - | 381 | (62.7) | 29 | |||
| Age (yrs) | ||||||||
| Mean ± SD | 71.3 ± 7.4 | 70.9 ± 8.0 | 0.622 | 71.6 ± 8.6 | ||||
| <65 | 58 | (19.6) | 64 | (21.6) | 0.430 | 133 | (21.9) | 8 |
| ≥65 | 229 | (77.4) | 215 | (72.6) | 471 | (77.5) | 40 | |
| Missing | 9 | 17 | 4 | |||||
| BMI (kg/m2) | ||||||||
| Mean ± SD | 24.2 ± 3.1 | 24.1 ± 3.2 | 0.742 | 24.3 ± 3.2 | ||||
| <24 | 130 | (43.9) | 134 | (45.3) | 0.967 | 277 | (45.6) | 27 |
| 24– < 27 | 90 | (30.4) | 89 | (30.1) | 207 | (34.0) | 13 | |
| ≥27 | 41 | (13.9) | 43 | (14.5) | 98 | (16.1) | 5 | |
| Missing | 35 | 30 | 26 | 3 | ||||
| Education | ||||||||
| <high school | 100 | (33.8) | 111 | (37.5) | 0.861 | 175 | (27.8) | 18 |
| High school | 85 | (28.7) | 86 | (29.1) | 225 | (37.0) | 17 | |
| >high school | 66 | (22.3) | 66 | (22.3) | 178 | (29.3) | 13 | |
| Missing | 45 | 33 | 30 | 0 | ||||
| Marital status* | ||||||||
| Single/widowed/separated/divorced | 44 | (14.9) | 30 | (10.1) | 0.047* | 55 | (9.0) | 6 |
| Married | 205 | (69.3) | 231 | (78.0) | 520 | (85.5) | 42 | |
| Missing | 47 | 35 | 33 | |||||
| Vasectomy | ||||||||
| No | 215 | (72.6) | 199 | (67.2) | 0.628 | 516 | (84.9) | 39 |
| Yes | 10 | (3.4) | 7 | (2.4) | 17 | (2.8) | 0 | |
| Missing | 71 | 90 | 75 | 9 | ||||
| Family history of PC | ||||||||
| No | 226 | (76.4) | 245 | (82.8) | 0.243 | 523 | (86.0) | 43 |
| Yes | 17 | (5.7) | 11 | (3.7) | 32 | (5.3) | 3 | |
| Missing | 53 | 40 | 53 | |||||
| Cigarette Smoking | ||||||||
| No | 153 | (51.7) | 159 | (53.7) | 0.561 | 293 | (48.2) | 20 |
| Yes | 143 | (48.3) | 135 | (45.6) | 315 | (51.8) | 28 | |
| Missing | 0 | 2 | 0 | 0 | ||||
| Alcohol drinking | ||||||||
| No | 199 | (67.2) | 208 | (70.2) | 0.459 | 428 | (70.4) | 28 |
| Yes | 95 | (32.1) | 87 | (29.4) | 179 | (29.4) | 20 | |
| Missing | 2 | 1 | 1 | 0 | ||||
| Betel nut chewing | ||||||||
| No | 281 | (94.9) | 281 | (94.9) | 0.845 | 578 | (95.1) | 44 |
| Yes | 13 | (4.4) | 12 | (4.1) | 28 | (4.6) | 3 | |
| Missing | 2 | 3 | 2 | 1 | ||||
| Clinical stageb | ||||||||
| Localized | 290 | (47.7) | 7 | |||||
| Locally advanced | 158 | (26.0) | 7 | |||||
| Bone metastasis | 154 | (25.3) | 34 | |||||
| Missing | 6 | 0 | ||||||
| Gleason score | ||||||||
| <6 | 255 | (41.9) | 11 | |||||
| 7 | 191 | (31.4) | 12 | |||||
| 8-10 | 154 | (25.3) | 25 | |||||
| Missing | 8 | 0 | ||||||
| Preoperative PSA (ng/ml) | ||||||||
| <10 | 152 | (25.0) | 5 | |||||
| 10- < 20 | 143 | (23.5) | 4 | |||||
| ≥20 | 295 | (48.5) | 38 | |||||
| Missing | 18 | 1 | ||||||
Abbreviation: BMI body mass index, PC: prostate cancer, PSA prostate-specific antigen
1Study site: North National Taiwan University Hospital, South: Kaohsiung Medical University Hospital and Kaohsiung Veterans General Hospital
*P-value < 0.05; aprostate cancer specific death; bTumor, node, metastasis system staging by American Joint Committee on Cancer (1997): Localized, T1/T2 N0 M0; Locally advanced, T3/T4 N1 M0; Bone Metastasis, M1
Odds ratio (OR) for cases and controls according to hair dyes use and regular exercise
| Cases | Controls | Crude OR (95 % CI) | AOR (95 % CI)a | AOR (95 % CI)b | |||
|---|---|---|---|---|---|---|---|
| Variables |
|
| |||||
| N | (%) | N | (%) | ||||
| Hair dyes | |||||||
| No | 197 | (66.6) | 231 | (78.0) | 1.00 | 1.00 | 1.00 |
| Yes | 95 | (32.1) | 64 | (21.6) | 1.74 (1.21–2.53)* | 1.86 (1.21–2.82)* | 2.15 (1.32–3.57)* |
| Missing | 4 | 1 | 4.69 (0.69–92.10) | 5.03 (0.73–98.83) | 5.40 (0.76–108.02) | ||
| Age of first use (yrs) | |||||||
| Never | 197 | (66.6) | 231 | (78.0) | 1.00 | 1.00 | 1.00 |
| ≥60 | 24 | (8.1) | 21 | (7.1) | 1.34 (0.72–2.49) | 1.23 (0.63–2.39) | 1.52 (0.71–3.30) |
| 50- < 60 | 28 | (9.5) | 21 | (7.1) | 1.56 (0.86–2.87)* | 2.19 (1.08–4.60)* | 2.64 (1.16–6.36)* |
| <50 | 29 | (9.8) | 16 | (5.4) | 2.13 (1.14–4.11)* | 2.32 (1.21–4.61)* | 2.25 (1.01–5.19)* |
| Missing | 18 | 7 | 3.02 (1.28–7.89) | 2.70 (1.04–7.86) | 4.29 (1.32–16.72) | ||
| P for trend | <0.01 | <0.01 | <0.01 | ||||
| Years of use (years) | |||||||
| Never | 197 | (66.6) | 231 | (78.0) | 1.00 | 1.00 | 1.00 |
| ≤10 | 40 | (13.5) | 35 | (11.8) | 1.34 (0.82–2.20) | 1.49 (0.87–2.59) | 1.57 (0.82–3.03) |
| >10 | 37 | (12.5) | 22 | (7.4) | 1.97 (1.13–3.50)* | 2.10 (1.15–3.92)* | 2.54 (1.23–5.41)* |
| Missing | 22 | 8 | 3.22 (1.46–7.87) | 3.23 (1.36–8.52) | 5.43 (1.82–20.13) | ||
| P for trend | 0.02 | <0.01 | <0.01 | ||||
| Frequency of use (times per year) | |||||||
| Never | 197 | (66.6) | 231 | (78.0) | 1.00 | 1.00 | 1.00 |
| ≤6 | 41 | (13.9) | 32 | (10.8) | 1.50 (0.91–2.49) | 1.64 (0.95–2.85) | 1.73 (0.91–3.32) |
| >6 | 35 | (11.8) | 25 | (8.4) | 1.64 (0.95–2.86) | 1.97 (1.07–3.69)* | 2.65 (1.26–5.78)* |
| Missing | 23 | 8 | 3.37 (1.53–8.19) | 2.82 (1.23–7.08) | 3.85 (1.41–11.74) | ||
| P for trend | 0.02 | <0.01 | <0.01 | ||||
| Year of first use | |||||||
| No | 197 | (66.6) | 231 | (78.0) | 1.00 | 1.00 | 1.00 |
| After 1980 | 5 | (1.7) | 3 | (1.0) | 1.95 (0.47–9.62) | 1.25 (0.23–6.83) | 0.89 (0.11–5.90) |
| Before 1980 | 76 | (25.7 | 55 | (18.6) | 1.62 (1.09–2.41)* | 1.87 (1.21–2.90)* | 2.16 (1.28–3.68)* |
| Missing | 18 | 7 | 3.02 (1.28–7.89) | 2.71 (1.04–7.89) | 4.32 (1.33–16.87) | ||
| Regular exercise | |||||||
| No | 126 | (42.6) | 120 | (40.5) | 1.00 | 1.00 | 1.00 |
| Yes | 166 | (56.1) | 168 | (56.8) | 0.93 (0.67–1.28) | 0.99 (0.69–1.43) | 1.01 (0.64–1.59) |
| Missing | 4 | 8 | 0.48 (0.02–5.03) | none | 1.03 (0.66–1.62) | ||
| Frequency of exercise (times per week) | |||||||
| No | 126 | (42.6) | 120 | (40.5) | 1.00 | 1.00 | 1.00 |
| 1-6 | 56 | (18.9) | 65 | (22.0) | 1.22 (0.79–1.89) | 0.94 (0.58–1.53) | 1.01 (0.55–1.86) |
| ≥7 | 110 | (37.2) | 103 | (34.8) | 0.98 (0.68–1.42) | 1.02 (0.68–1.54) | 0.97 (0.58–1.62) |
| Missing | 4 | 8 | 0.48 (0.12–1.55) | 1.57 (0.25–12.15) | 0.97 (0.11–8.50) | ||
Abbreviation: AOR: adjusted OR; OR: odds ratio; PC: prostate cancer
aAdjusting for age, and family history of PC, bAdjusting for age, marital status, blood type, education, family history of PC, cigarette smoking, alcohol drinking and betel nut chewing
*P-value < 0.05
Fig. 2Cumulative incidence estimates of prostate-cancer specific death and other-cause death categorized by regular exercise or hair dye use: a by regular exercise; b by hair dye use
Prostate-cancer-specific death according to hair dye use and regular exercise in a Cox regression model
| N | Total 608 | Prostate-cancer-specific death 48 | HR | (95 % CI) | AHRa | (95 % CI) | |
|---|---|---|---|---|---|---|---|
| Variables | N (%) | N | |||||
| Hair dyes | |||||||
| No | 443 | (72.9) | 35 | 1.00 | 1.00 | ||
| Yes | 161 | (54.4) | 13 | 0.89 | (0.45-1.65) | 1.14 | (0.47-2.59) |
| Missing | 4 | 0 | |||||
| Years of use | |||||||
| Never | 443 | (72.9) | 35 | 1.00 | 1.00 | ||
| ≤10 years | 85 | (14.0) | 9 | 1.16 | (0.52-2.31) | 1.46 | (0.54-3.56) |
| >10 years | 64 | (10.5) | 2 | 0.35 | (0.06-1.15) | 0.33 | (0.02-1.74) |
| Missing | 16 | 2 | |||||
| Frequency of use (times per year | |||||||
| Never | 443 | (72.9) | 35 | 1.00 | 1.00 | ||
| ≤6 | 83 | (13.7) | 5 | 0.75 | (0.26-1.74) | 0.62 | (0.14-1.94) |
| >6 | 63 | (10.4) | 7 | 1.07 | (0.43-2.28) | 2.15 | (0.70-6.03) |
| Missing | 19 | 1 | |||||
| Regular exercise | |||||||
| No | 252 | (41.4) | 34 | 1.00 | 1.00 | ||
| Yes | 353 | (58.1) | 14 | 0.27 | (0.14-0.50)* | 0.37 | (0.16-0.83)* |
| Missing | 3 | 0 | |||||
| Frequency of exercise (times per week) | |||||||
| Never | 252 | (41.4) | 34 | 1.00 | 1.00 | ||
| 1-6 | 161 | (26.5) | 7 | 0.34 | (0.14-0.73)* | 0.66 | (0.22-1.82) |
| ≥7 | 188 | (30.9) | 6 | 0.20 | (0.08-0.45)* | 0.23 | (0.07-0.65)* |
| Missing | 7 | 1 | |||||
| Clinical stageb | |||||||
| Localized | 290 | (47.7) | 7 | 1.00 | 1.00 | ||
| Locally advanced | 158 | (26.0) | 7 | 1.95 | (0.67-5.71) | 1.56 | (0.41-5.69) |
| Bone metastasis | 154 | (25.3) | 34 | 12.10 | (5.64-29.99)* | 10.15 | (3.22-35.98* |
| Missing | 6 | 0 | |||||
Abbreviation: AHR adjusted HR, HR: hazard ratio
*P-value < 0.05; aAdjusting for clinical stage, PSA, age, marital status, blood type, education, family history of PC, cigarette smoking, alcohol drinking, and betel nut chewing
bTumor, node, metastasis system staging by American Joint Committee on Cancer (1997): Localized, T1/T2 N0 M0; Locally advanced, T3/T4 N1 M0; Bone Metastasis, M1